Answers are grounded in this paper and cite their sources.
Biomarkers reflecting real-time response to therapy and recurrence are lacking. We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients.
No takes yet. Share an insight, caveat, or question.
Jamieson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: